Interruption of HBV intrauterine transmission: A clinical study

Table 1 Comparison of HBV DNA values before and after administration of the reagents

Group	n	Log10 HBV DNA beforeadministration of drugs(copies/ml)	Log10 HBV DNA beforelabor(copies/ml)	Minus value of log10 HBV DNA before and after administration of agents (copies/ml)
HBIG	56	7.38 ± 1.17a	5.28 ± 2.77bd	2.09 ± 2.28b
Lamivudine	43	7.49 ± 0.54a	5.33 ± 1.34bd	2.16 ± 1.27b
Conrol	52	7.05 ± 1.29a	6.23 ± 3.66c	0.82 ± 2.73b

^aP > 0.05 vs other groups;

^bP > 0.05 between HBIG group and lamivudine group;

^cP < 0.05 vs HBIG group or lamivudine group;

^dP < 0.05 (before vs after administration).

Table 2 Incidence of neonatal intrauterine infection in 3 groups

Group	n	HBsAg(+) n	HBeAg(+) n	Intrauterine infection
				n	%
HBIG	56	3	7	9	16.1a
Lamivudine	43	1	7	7	16.3a
Control	52	8	11	17	32.7b

^aP > 0.05 between HBIG group and lamivudine group;

^bP < 0.05 vs HBIG group or lamivudine group.